SCHEMBL30940966

SCHEMBL30940966

CC(C)(C)OC(=O)N(CCc1ccccc1)CC1CC(C[C@H]2C[C@H](O)[C@@H]3OC(C)(C)O[C@H]23)C1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 4/20 0.33
▸ CHRNB2 P17787 1/20 0.32
▸ CHRNB4 P30926 1/20 0.32
▸ CHRNA3 P32297 1/20 0.32
▸ CHRNA4 P43681 1/20 0.32
▸ HDAC3 O15379 1/20 0.32
▸ HDAC1 Q13547 1/20 0.32
▸ HDAC2 Q92769 1/20 0.32
▸ NCOR2 Q9Y618 1/20 0.32
▸ SLC18A3 Q16572 1/20 0.31
▸ CA12 O43570 1/20 0.30
▸ CA1 P00915 1/20 0.30
▸ CA7 P43166 1/20 0.30
▸ CA14 Q9ULX7 1/20 0.30
▸ DAGLB Q8NCG7 1/20 0.30
▸ DAGLA Q9Y4D2 1/20 0.30
▸ MEN1 O00255 1/20 0.30
▸ NPC1 O15118 1/20 0.30
▸ RAB9A P51151 1/20 0.30
▸ KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25049170 0.87 L3MBTL1 (0.36) L3MBTL1CHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL30941658 0.86 CHRNB2 (0.30) CHRNB2CHRNB4CHRNA3CHRNA4DAGLB
SCHEMBL30940735 0.75 PPARG (0.34) —
SCHEMBL31617945 0.73 SLC6A2 (0.43) L3MBTL1HDAC3HDAC1HDAC2NCOR2
SCHEMBL30941778 0.72 CA14 (0.35) CA14
SCHEMBL30941205 0.72 CYP2C19 (0.43) L3MBTL1MEN1KMT2A
SCHEMBL25049172 0.70 OPRM1 (0.45) L3MBTL1SLC18A3TDP1
SCHEMBL30941013 0.68 SMN1; SMN2 (0.43) L3MBTL1MEN1NPC1RAB9AKMT2A
SCHEMBL5968911 0.68 L3MBTL1 (0.37) L3MBTL1HDAC3HDAC1HDAC2NCOR2
SCHEMBL4781274 0.68 HDAC3 (0.48) L3MBTL1HDAC3HDAC1HDAC2NCOR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250188110-A1 SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) 2025-06-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250188110-A1 SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION KMT5A, KMT5B, KMT5C L3MBTL1 388/4885CHRNB2 2708/4885CHRNB4 1686/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback